Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Merbarone is a small molecule anticancer agent and a nonsedating derivative of thiobarbituric acid. It acts as a catalytic inhibitor of topoisomerase II, blocking the enzyme's ability to mediate DNA cleavage without stabilizing DNA-topoisomerase II covalent complexes. Unlike other topoisomerase II inhibitors such as etoposide, merbarone does not intercalate into DNA or bind in the minor groove but interferes with DNA replication by binding directly to topoisomerase II at a domain potentially shared with other cleavage-enhancing agents. Merbarone has demonstrated cytotoxic and genotoxic effects in preclinical studies and was evaluated in clinical trials for its antineoplastic (anticancer) activity[1][2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on merbarone.